Keywords include immune microenvironment, pyroptosis, etc. In a relatively new study (21), researchers found that S100A2 is a prognostic biomarker that participates in the immune microenvironment of pancreatic cancer and predicts the response to immunotherapy. This evidence concerns the gene S100A2 and familial pancreatic carcinoma.